Cantor Fitzgerald analyst Charles Duncan raised his price target for Cytokinetics to $20 from $14 and reiterates an Overweight rating on the shares ahead of the annual Heart Failure Society of America meeting, which starts September 13. The analyst expects top-line Phase 1 CK-274 results in healthy volunteers. Cytokinetics first premiered CK-274, a cardiac sarcomere inhibitor, for the treatment of hypertrophic cardiomyopathy last October, and management has expressed a high level of confidence in the therapeutic candidate's best-in-class potential, Duncan tells investors in a research note.